bioRxiv Science⌕ Search

Biology subjects

Burgering, B. M.

Publications and source records attributed to Burgering, B. M..

4 recordsLinked to original sources

Single Cell Proteomics reveals partial uncoupling of the Glycerol-3-Phosphate shuttle to compensate for Electron Transport Chain dysfunction in Alexander Disease GFAP mutations

Alexander disease (AxD) is a rare genetic leukodystrophy caused by dominant mutations in the gene coding for the astrocytic intermediate filament protein Glial Fibrillary Acidic Protein (GFAP). Understanding disease mechanisms is complicated by the fact that mutant GFAP promotes further GFAP accumulation, making it difficult to distinguish mutation-specific effects from those caused by elevated GFAP levels. Here, we performed mass spectrometry-based single cell proteomics to investigate proteomic alterations associated with increasing levels of wildtype GFAP and a common AxD-causing mutant GFAP R239C. By analyzing individual cells spanning a broad range of GFAP expression levels, we separated dosage-dependent effects from mutation-specific responses. Cells expressing high levels of wildtype GFAP increasingly resembled R239C-expressing cells at the proteomic level, supporting a role for GFAP accumulation in disease pathogenesis. In contrast, mutant GFAP specifically correlated with increased mitochondrial antioxidant enzymes and remodeling of the proteasome tailored toward ATP- and ubiquitin-independent degradation of oxidized proteins. Integration with proteomics data from patient-derived cortical organoids revealed increased abundance of nuclear-encoded mitochondrial proteins and respiratory chain assembly factors without corresponding changes in mitochondrially encoded proteins, suggesting impaired electron transport chain (ETC) assembly. Consistent with this, AxD cells displayed reduced oxygen consumption, increased glycolytic activity, enhanced utilization of the cytosolic part of the glycerol-3-phosphate (G3P) shuttle, and accumulation of triacylglycerides and lipid droplets. We propose that ETC dysfunction promotes partial uncoupling of the G3P shuttle, allowing sustained regeneration of cytosolic NAD to support glycolysis while diverting G3P toward lipid synthesis and storage. By regenerating NAD through the G3P shuttle rather than lactate fermentation, AxD astrocytes may sustain glycolytic flux while preserving lactate production, an important metabolic substrate for neighboring neurons. Together, our findings identify ETC dysfunction as a central feature of AxD and suggest that metabolic adaptation through the G3P shuttle links mitochondrial dysfunction to glycolytic reprogramming and lipid accumulation. More broadly, these results provide new insight into how astrocyte dysfunction drives molecular pathways implicated in neurodegeneration.

neuroscience↗

Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapies

Poor therapeutic response in subsets of breast cancer (BC) patients poses an ongoing challenge. Here, we present a biomarker-guided characterization of 44 patient-derived BC organoids, with the aim of modeling resistant disease with greater fidelity and developing an in-vitro system grounded in clinical data for testing alternative treatment strategies. We utilized patient transcriptomic and outcome data from the I-SPY2 clinical trial to develop predictive models of response to a range of therapies, using only organoid-detectable biomarkers as input. A model predicting response to veliparib-platinum chemotherapy (VP) in triple-negative BC (TNBC) was validated in organoids, showing that in vitro drug responses matched predictions from the patient data-derived model. A drug screen in VP-resistant TNBC organoids identified combination treatments that overcame resistance to cisplatin, including pro-apoptotic therapies. This demonstrates that gene expression-based resistance models derived from patient data can be successfully modeled in organoids that can then be used for therapeutic evaluation.

cancer biology↗

Hsa-miR-31-5p controls a metabolic switch in psoriatic keratinocytes that identifies therapeutic intervention

Psoriasis is characterized by a combination of keratinocyte hyperproliferation and immune cell activation. Immune cell activation requires increased glucose consumption, consequently limiting glucose availability for other cell types like keratinocytes. In psoriasis Hsa-microRNA-31-5p (miR-31) is highly expressed in keratinocytes. Here we show that miR-31 expression in keratinocytes is induced by limited glucose availability and increases survival under limiting glucose conditions, by increasing glutamine metabolism. In addition, miR-31 induced glutamine metabolism results in secretion of specific metabolites (aspartate and glutamate) but also immuno-modulatory factors. We show that this miR-31-induced secretory phenotype is sufficient to induce Th17 cell differentiation, a hallmark of psoriasis. Inhibition of glutaminase (GLS) using CB-839 impedes miR31-induced metabolic rewiring and secretion of immuno-modulatory factors. Concordantly, pharmacological targeting of GLS alleviated psoriasis pathology in a mouse model of psoriasis. Together our data illustrate an emerging concept of metabolic interaction across cell compartments that characterizes disease development, which can be employed to design effective treatment options for disease, as shown here for psoriasis.

immunology↗

Rewiring glucose metabolism improves 5-FU efficacy in glycolytic p53-deficient colorectal tumors

5-fluorouracil (5-FU) is the backbone for chemotherapy in colorectal cancer (CRC). Response rates in patients are, however, limited to 50%. Despite the importance of 5-FU, the molecular mechanisms by which it induces toxicity remain unclear, limiting the development of strategies to improve efficacy. How fundamental aspects of cancer, such as driver mutations and phenotypic intra-tumor heterogeneity, relate to the 5-FU response is also ill-defined. This is largely due to the shortage of mechanistic studies executed in pre-clinical models that can faithfully recapitulate key CRC features. Here, we analyzed the 5-FU response in human organoids genetically engineered to reproduce the different stages of CRC progression. We find that 5-FU induces pyrimidine imbalance, which leads to DNA damage and cell death. Actively proliferating cancer (stem) cells are accordingly efficiently targeted by 5-FU. Importantly, p53 behaves as a discriminating factor for 5-FU sensitivity, whereas p53-deficiency leads to DNA damage-induced cell death, active p53 protects from these effects through inducing cell cycle arrest. Moreover, we find that targeting the Warburg effect, by rewiring glucose metabolism, enhances 5-FU toxicity by further altering the nucleotide pool and without increasing toxicity in healthy-non-transformed cells. Thus, targeting cancer metabolism in combination with replication stress-inducing chemotherapies emerges as a promising strategy for CRC treatment.

cancer biology↗